AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03131687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT03131687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03131687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05677958 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 125 mL Fortimel/Nutridrink Compact Protein
Description: 125 mL Fortimel/Nutridrink Compact Protein®\* two servings per day (300 kcal, 18 g protein per serving).
Study NCT03945318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Single Dose
Description: A solution for IV infusion administered as a single dose.
Study NCT03945318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Single Dose
Description: A solution by IV infusion administered as a single dose.
Study NCT03945318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Multiple Doses
Description: A solution for IV infusion or SC injections (Part 3 only) administered as multiple doses.
Study NCT03945318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Multiple Doses
Description: A solution by IV infusion administered as multiple doses.
Study NCT03945318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301 Single Dose
Description: SC injection administration as a single dose using vials or pre-filled syringes (PFS) (Part 4 only).
Study NCT01904032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 international units (IUs) weekly Vitamin D3
Study NCT01904032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 comparator
Description: 5,000 international units (IUs) of a weekly Vitamin D3 comparator
Study NCT04555707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: 30mg PO BID started within 10 days of baseline
Study NCT04555707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriene and betamethasone dipropionate
Description: 1 application daily starting at baseline and continuing for 4 weeks; those achieving clear or almost clear PGA at week 4 will continue application twice weekly on Monday and Thursday in combination with Otezla. Enstilar application is discontinued at week 16 and study participation continues until week 20.
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Therapy Sessions
Description: One-on-one sessions with a counselor
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Therapy Sessions
Description: One-on-one sessions with a counselor
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication-Assisted Treatment
Description: Buprenorphine or Extended-Release Naltrexone
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication-Assisted Treatment
Description: Buprenorphine or Extended-Release Naltrexone
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Specialist Support
Description: Individual and/or group sessions with a certified peer recovery specialist
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Recovery Specialist Support
Description: Individual and/or group sessions with a certified peer recovery specialist
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy Sessions
Description: Group therapy sessions
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychiatric Consultation
Description: Access to psychiatric consultation
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric Consultation
Description: Access to psychiatric consultation
Study NCT03367234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards for engagement in specified recovery behaviors
Study NCT00098670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC
Study NCT00098670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00098670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT01187277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
Study NCT01187277 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional plus robotic gait assisted therapy
Description: individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
Study NCT03655457 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 1 Poractant alfa
Description: Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
Study NCT03655457 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: group 2 beractant
Description: lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2\*100 mg) on Day 8.
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
Study NCT03762681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7239958
Description: Solution for injection, subcutaneous use (SC).
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
Study NCT02397382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
Study NCT02038387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normocaloric low cholesterol diet
Study NCT02847286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Ring-004
Description: Treatment A: Dapivirine Ring-004 for 28 days
Study NCT02847286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Ring-004 for 28 days along with clotrimazole
Description: Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
Study NCT02847286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Treatment C: Clotrimazole, 5 g per day for 7 days
Study NCT05812742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early intervention programme
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Study NCT05812742 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Study NCT05812742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Description: For more information, please go to the original registration of the RCT-study (NCT02337101) or the published article (PMID: 31891145).
Study NCT03899831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Function-Based Elopement Treatment (FBET)
Description: The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~* to create a safer environment~* teach adaptive skills to replace elopement~* arrange the environment and rewards to reduce elopement~* and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding.
Study NCT03899831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education Program (PEP)
Description: The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
Study NCT03329677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transference-focused Psychotherapy (TFP)
Description: Participants receive 18 months of bi-weekly TFP. Each sessions lasts 45 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
Study NCT04016155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott FreeStyle Libre
Description: Flash CGMS
Study NCT04016155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Own SMBG
Description: Market SMBG
Study NCT04263038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Anticoagulation
Study NCT04263038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug without active agent
Study NCT00681668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 150-800 mg, oral, twice a day (bid)
Study NCT00862836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 100mg doses orally, once daily
Study NCT03019419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: 4mg/d or 8mg/d
Study NCT03019419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04554719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI
Description: Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-FAPI dose is about 1.85-3.7 MBq/kg body weight (0.05-0.1 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
Study NCT04554719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
Study NCT04554719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study NCT01755377 — intervention group
Intervention type: DRUG
Intervention: Benznidazole
Study NCT03762681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium chloride solution for injection, SC
Study NCT03095469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
Study NCT03095469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%NaCl solution
Description: when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
Study NCT02868606 — intervention group
Intervention type: OTHER
Intervention: Physiologic Insulin Therapy
Study NCT02868606 — intervention group
Intervention type: OTHER
Intervention: Sliding-Scale Insulin Therapy
Study NCT02859740 — intervention group
Intervention type: OTHER
Intervention: SIGAM Questionnaire
Study NCT00611975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
Study NCT00611975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
Study NCT03882086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
Study NCT04411056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barrier box
Description: Placement of barrier box ( a plastic box for shielding)
Study NCT04175041 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study NCT02303197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChiNing decoction
Description: ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
Study NCT00003896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00003896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Study NCT00003896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02858024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and no tampons
Description: Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
Study NCT02858024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 with tampons
Description: followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
Study NCT02858024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 with no menses
Description: Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
Study NCT02858024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and same ring inserted after menses
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
Study NCT02858024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapivirine Vaginal Ring-004 and new ring inserted after menses
Description: Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
Study NCT04127396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles. Body weight (BW)>60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW\<60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
Study NCT04127396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization(TACE)
Description: TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
Study NCT04127396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib capsules will be administered orally, 400 mg twice daily (BID) oral dosing.
Study NCT04127396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization(TACE)
Description: TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
Study NCT03130270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate tablet
Description: Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment.
Study NCT02559570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study NCT02559570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose A
Description: Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study NCT02559570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose B
Description: Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study NCT02559570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN Dose C
Description: Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
Study NCT02559570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIN 145 µg
Description: Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
Study NCT00722683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging with Contrast
Description: An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times.
Study NCT01396551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of anchored Beacon transponder in the lung
Description: Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
Study NCT02648464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Study NCT02648464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02335385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single incision laparoscopic varicocelectomy
Description: bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
Study NCT02335385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional transperitoneal laparoscopic varicocelectomy
Description: bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy